151 related articles for article (PubMed ID: 18492917)
1. Breast stromal enhancement on MRI is associated with response to neoadjuvant chemotherapy.
Hattangadi J; Park C; Rembert J; Klifa C; Hwang J; Gibbs J; Hylton N
AJR Am J Roentgenol; 2008 Jun; 190(6):1630-6. PubMed ID: 18492917
[TBL] [Abstract][Full Text] [Related]
2. MRI enhancement in stromal tissue surrounding breast tumors: association with recurrence free survival following neoadjuvant chemotherapy.
Jones EF; Sinha SP; Newitt DC; Klifa C; Kornak J; Park CC; Hylton NM
PLoS One; 2013; 8(5):e61969. PubMed ID: 23667451
[TBL] [Abstract][Full Text] [Related]
3. DCE-MRI analysis methods for predicting the response of breast cancer to neoadjuvant chemotherapy: pilot study findings.
Li X; Arlinghaus LR; Ayers GD; Chakravarthy AB; Abramson RG; Abramson VG; Atuegwu N; Farley J; Mayer IA; Kelley MC; Meszoely IM; Means-Powell J; Grau AM; Sanders M; Bhave SR; Yankeelov TE
Magn Reson Med; 2014 Apr; 71(4):1592-602. PubMed ID: 23661583
[TBL] [Abstract][Full Text] [Related]
4. Effect of Imaging Parameter Thresholds on MRI Prediction of Neoadjuvant Chemotherapy Response in Breast Cancer Subtypes.
Lo WC; Li W; Jones EF; Newitt DC; Kornak J; Wilmes LJ; Esserman LJ; Hylton NM
PLoS One; 2016; 11(2):e0142047. PubMed ID: 26886725
[TBL] [Abstract][Full Text] [Related]
5. Accuracy of Contrast-Enhanced Ultrasound Compared With Magnetic Resonance Imaging in Assessing the Tumor Response After Neoadjuvant Chemotherapy for Breast Cancer.
Lee SC; Grant E; Sheth P; Garcia AA; Desai B; Ji L; Groshen S; Hwang D; Yamashita M; Hovanessian-Larsen L
J Ultrasound Med; 2017 May; 36(5):901-911. PubMed ID: 28150325
[TBL] [Abstract][Full Text] [Related]
6. Optimized breast MRI functional tumor volume as a biomarker of recurrence-free survival following neoadjuvant chemotherapy.
Jafri NF; Newitt DC; Kornak J; Esserman LJ; Joe BN; Hylton NM
J Magn Reson Imaging; 2014 Aug; 40(2):476-82. PubMed ID: 24347097
[TBL] [Abstract][Full Text] [Related]
7. Radiologic complete response (rCR) in contrast-enhanced magnetic resonance imaging (CE-MRI) after neoadjuvant chemotherapy for early breast cancer predicts recurrence-free survival but not pathologic complete response (pCR).
Gampenrieder SP; Peer A; Weismann C; Meissnitzer M; Rinnerthaler G; Webhofer J; Westphal T; Riedmann M; Meissnitzer T; Egger H; Klaassen Federspiel F; Reitsamer R; Hauser-Kronberger C; Stering K; Hergan K; Mlineritsch B; Greil R
Breast Cancer Res; 2019 Jan; 21(1):19. PubMed ID: 30704493
[TBL] [Abstract][Full Text] [Related]
8. Analysis of kinetic curve and model-based perfusion parameters on dynamic contrast enhanced MRI in breast cancer patients: Correlations with dominant stroma type.
Yim H; Kang DK; Jung YS; Jeon GS; Kim TH
Magn Reson Imaging; 2016 Jan; 34(1):60-5. PubMed ID: 26234500
[TBL] [Abstract][Full Text] [Related]
9. Background Parenchymal Enhancement on Preoperative Magnetic Resonance Imaging: Association With Recurrence-Free Survival in Breast Cancer Patients Treated With Neoadjuvant Chemotherapy.
Choi JS; Ko ES; Ko EY; Han BK; Nam SJ
Medicine (Baltimore); 2016 Mar; 95(9):e3000. PubMed ID: 26945421
[TBL] [Abstract][Full Text] [Related]
10. Dynamic contrast-enhanced MRI for prediction of breast cancer response to neoadjuvant chemotherapy: initial results.
Loo CE; Teertstra HJ; Rodenhuis S; van de Vijver MJ; Hannemann J; Muller SH; Peeters MJ; Gilhuijs KG
AJR Am J Roentgenol; 2008 Nov; 191(5):1331-8. PubMed ID: 18941065
[TBL] [Abstract][Full Text] [Related]
11. Contrast-enhanced MRI after neoadjuvant chemotherapy of breast cancer: lesion-to-background parenchymal signal enhancement ratio for discriminating pathological complete response from minimal residual tumour.
Kim SY; Cho N; Shin SU; Lee HB; Han W; Park IA; Kwon BR; Kim SY; Lee SH; Chang JM; Moon WK
Eur Radiol; 2018 Jul; 28(7):2986-2995. PubMed ID: 29380033
[TBL] [Abstract][Full Text] [Related]
12. The assessment of breast cancer response to neoadjuvant chemotherapy: comparison of magnetic resonance imaging and 18F-fluorodeoxyglucose positron emission tomography.
Park JS; Moon WK; Lyou CY; Cho N; Kang KW; Chung JK
Acta Radiol; 2011 Feb; 52(1):21-8. PubMed ID: 21498321
[TBL] [Abstract][Full Text] [Related]
13. Role of diffusion-weighted imaging as an adjunct to contrast-enhanced breast MRI in evaluating residual breast cancer following neoadjuvant chemotherapy.
Hahn SY; Ko EY; Han BK; Shin JH; Ko ES
Eur J Radiol; 2014 Feb; 83(2):283-8. PubMed ID: 24315957
[TBL] [Abstract][Full Text] [Related]
14. Prognostic Value of 68Ga-NOTA-RGD PET/CT for Predicting Disease-Free Survival for Patients With Breast Cancer Undergoing Neoadjuvant Chemotherapy and Surgery: A Comparison Study With Dynamic Contrast Enhanced MRI.
Kim YI; Yoon HJ; Paeng JC; Cheon GJ; Lee DS; Chung JK; Kim EE; Moon WK; Kang KW
Clin Nucl Med; 2016 Aug; 41(8):614-20. PubMed ID: 27276207
[TBL] [Abstract][Full Text] [Related]
15. Breast parenchymal signal enhancement ratio at preoperative magnetic resonance imaging: association with early recurrence in triple-negative breast cancer patients.
Park VY; Kim EK; Kim MJ; Yoon JH; Moon HJ
Acta Radiol; 2016 Jul; 57(7):802-8. PubMed ID: 26516288
[TBL] [Abstract][Full Text] [Related]
16. Perfusion Parameters on Breast Dynamic Contrast-Enhanced MRI Are Associated With Disease-Specific Survival in Patients With Triple-Negative Breast Cancer.
Park VY; Kim EK; Kim MJ; Yoon JH; Moon HJ
AJR Am J Roentgenol; 2017 Mar; 208(3):687-694. PubMed ID: 28004976
[TBL] [Abstract][Full Text] [Related]
17. Relationship of clinical and pathologic response to neoadjuvant chemotherapy and outcome of locally advanced breast cancer.
Gajdos C; Tartter PI; Estabrook A; Gistrak MA; Jaffer S; Bleiweiss IJ
J Surg Oncol; 2002 May; 80(1):4-11. PubMed ID: 11967899
[TBL] [Abstract][Full Text] [Related]
18. Prognostic value of DCE-MRI in breast cancer patients undergoing neoadjuvant chemotherapy: a comparison with traditional survival indicators.
Pickles MD; Lowry M; Manton DJ; Turnbull LW
Eur Radiol; 2015 Apr; 25(4):1097-106. PubMed ID: 25424563
[TBL] [Abstract][Full Text] [Related]
19. Monitoring neoadjuvant chemotherapy in breast cancer patients: improved MR assessment at 3 T?
Heldahl MG; Lundgren S; Jensen LR; Gribbestad IS; Bathen TF
J Magn Reson Imaging; 2011 Sep; 34(3):547-56. PubMed ID: 21761463
[TBL] [Abstract][Full Text] [Related]
20. Intratumor partitioning and texture analysis of dynamic contrast-enhanced (DCE)-MRI identifies relevant tumor subregions to predict pathological response of breast cancer to neoadjuvant chemotherapy.
Wu J; Gong G; Cui Y; Li R
J Magn Reson Imaging; 2016 Nov; 44(5):1107-1115. PubMed ID: 27080586
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
